Pfizer, BioNTech launch trial of omicron-specific COVID-19 vaccine

Pfizer and BioNTech said Tuesday that they have initiated a clinical study to assesses the safety and efficacy of a COVID-19 vaccine for adults aged 18 to 55 years that specifically targets the omicron variant of SARS-CoV-2. The study will consist of 1,420 participants in three cohorts, including separate cohorts of people who have received two or three doses of the current Pfizer-BioNTech

Read the full article here

Related Articles

url_id=https%3A%2F%2Fwww.healio.com%2Fnews%2Fhematology-oncology%2F20250630%2Fnearly-75-of-pivotal-cancer-trials-in-past-5-years-exclude-people-living-with-hiv&page=1&sort=1